Proteins

# **Screening Libraries**

# Inhibitors

## **Product** Data Sheet

# (Rac)-HAMI 3379

Cat. No.: HY-112248 CAS No.: 712313-35-4 Molecular Formula: C<sub>34</sub>H<sub>45</sub>NO<sub>8</sub> Molecular Weight: 595.72

Target: Leukotriene Receptor Pathway: GPCR/G Protein

Storage: -20°C, sealed storage, away from moisture

\* In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

### **SOLVENT & SOLUBILITY**

In Vitro

DMSO: 100 mg/mL (167.86 mM; Need ultrasonic)

| Preparing<br>Stock Solutions | Solvent Mass<br>Concentration | 1 mg      | 5 mg      | 10 mg      |
|------------------------------|-------------------------------|-----------|-----------|------------|
|                              | 1 mM                          | 1.6786 mL | 8.3932 mL | 16.7864 mL |
|                              | 5 mM                          | 0.3357 mL | 1.6786 mL | 3.3573 mL  |
|                              | 10 mM                         | 0.1679 mL | 0.8393 mL | 1.6786 mL  |

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (4.20 mM); Clear solution
- 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: 2.5 mg/mL (4.20 mM); Suspended solution; Need ultrasonic
- 3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (4.20 mM); Clear solution

### **BIOLOGICAL ACTIVITY**

| Description               | (Rac)-HAMI 3379 is the racemate of HAMI 3379. HAMI 3379 is a potent and selective Cysteinyl leukotriene (CysLT $_2$ ) receptor antagonist $^{[1][2]}$ .  |  |
|---------------------------|--|--|
| IC <sub>50</sub> & Target | CysLT <sub>2</sub>   |  |
| In Vitro                  | In a $CysLT_2$ receptor reporter cell line, HAMI3379 antagonizes leukotriene $D_4$ - (LTD $_4$ -) and leukotriene $C_4$ - (LTC $_4$ -) induced intracellular calcium mobilization with IC $_{50}$ values of 3.8 nM and 4.4 nM respectively <sup>[1]</sup> .  MCE has not independently confirmed the accuracy of these methods. They are for reference only. |  |

### **CUSTOMER VALIDATION**

• Sci Immunol. 2022 Mar 4;7(69):eabf6734.

See more customer validations on  $\underline{www.MedChemExpress.com}$ 

### **REFERENCES**

[1]. Wunder F, et al. Pharmacological characterization of the first potent and selective antagonist at the cysteinyl leukotriene 2 (CysLT(2)) receptor. Br J Pharmacol. 2010 May;160(2):399-409.

[2]. Zhang XY, et al. HAMI 3379, a CysLT2 receptor antagonist, attenuates ischemia-like neuronal injury by inhibiting microglial activation. J Pharmacol Exp Ther. 2013 Aug;346(2):328-41.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Page 2 of 2 www.MedChemExpress.com